Background: Acne vulgaris is a common cutaneous disorder involving dysfunction of the pilo-sebaceous unit. Acne vulgaris affects up to 80% of Americans at some point in their lives. Though prevalent most frequently in adolescents, it may persist well into adulthood in some individuals

Aim of Work: The aim of this study is to evaluate the serum levels of Fetuin-A in patients with acne vulgaris and to assess it relation to the clinical severity of disease.

Methods: This case-control study was conducted in Outpatient Clinic of Dermatology and Andrology, Department of Benha University. The study included 80 participants; 60 patients suffering from acne vulgaris, in addition to 20 apparently healthy, age and sex matched individuals as control group, serum level of fetuin A  was be assessed in all participants,

Results: the result of the study revealed there was negative non-significant correlation between Serum Fetuin A and sex, course of disease, Stress, Sun Exposure, Relation to Smoking ,Post Acne Scar , the age and GAGS score,

Conclusion: Serum fetuin-A levels are detected higher in patients with acne. Also, there are no statistically significant relation between it and gender, age, Duration of disease, course of disease and in terms of   stress, Sun Exposure, Smoking, Post Acne Scar, Family History, Diet & PIH.

1. Jahns AC & Alexeyev OA, (2014): Нree-dimensional distribution of Propionibacterium acnes biofilms in human skin. Exp Dermatol 23:687-689.
2. Bhate K, Williams HC(2017); Epidemiology of acne vulgaris. Br J Dermatol;168:474-485.
3. Haukeland JW, Dahl TB, Yndestad A, et al., (2012): Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol . 166:503–510.
4. Sun Q,Cornelis MC, Manson JE, Hu FB, (2013): Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the US. Diabetes .;62:49–55.
5. Bakris GL & Molitch M.(2014): Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care ;37:867–875.
6. Cubukcuoglu T., Rasschaert N., Kacan C., Gul C. and Yavuz M (2013): Relationship between fetuin-A level and cardiovascular risk factors in peritoneal dialysis patients, Turkish Nephrology Dialysis and Transplantation Journal; 22 (1): 78-9.
7. Pateinakis P., Papagianni A., Douma S., et al., (2013): Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients, BMC Nephrology Journal; 14: 122.
8. Gangneux C., Daveau M., Hiron M., et al., (2003): The inflammation induced down regulation of plasma fetuin-A (α2HS-glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighboring binding sites. Nucleic Acid Research Journal; 31(20): 5957-70.
9. Doshi A, Zaheer A and Stiller MJ (1997): A comparison of current acne grading system and proposal of a noval system. Int J Dermatol.;36:416-8. 
10. Costa A, Alchorne MMdA and Goldschmidt MCB. (2008): Fatores etiopatogênicos da acne vulgar. Anais brasileiros de dermatologia.
11. Tvrzicka E, Kremmyda L-S, Stankova B, et al., (2011): FATTY ACIDS AS BIOCOMPOUNDS: THEIR ROLE IN HUMAN METABOLISM, HEALTH AND DISEASE-A REVIEW. PART 1: CLASSIFICATION, DIETARY SOURCES AND BIOLOGICAL FUNCTIONS. Biomedical Papers of the Medical Faculty of Palacky University in Olomouc 155.
12. Sindhu S, Akhter N, Shenouda S, et al., (2016): Plasma fetuin-A/α2-HS-glycoprotein correlates negatively with inflammatory cytokines, chemokines and activation biomarkers in individuals with type-2 diabetes.
13. Lebreton J, Joisel F, Raoult J, et al. (1979): Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. The Journal of clinical investigation 64: 1118-1129.
14. Wang X-Q, S Hung B, Kempf M, et al., (2009): Fetuin-A promotes primary keratinocyte migration: Independent of epidermal growth factor receptor signalling. Experimental dermatology; 19: e289-292.
15. Li W, Zhu S, Li J, et al. (2011):  A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation.  PloS one 6: e16945.
16. Demetriou M, Binkert C, Sukhu B et al., (1996): Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist.  J Biol Chem.;  271: 12755-12761
17. Haasemann M, Nawratil P and Müller-Esterl W. (1991): Rat tyrosine kinase inhibitor shows sequence similarity to human α 2-HS glycoprotein and bovine fetuin. Biochemical journal 274: 899-902.
18. Goustin A-S and Abou-Samra AB. (2011): The “thrifty” gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cellular signalling 23: 980-990.
19. Ix JH, Chertow GM, Shlipak MG, et al. (2006): Fetuin-A and kidney function in persons with coronary artery disease—data from the Heart and Soul Study. Nephrology Dialysis Transplantation 21: 2144-2151.
20. Szweras M, Liu D, Partridge EA, et al. (2002): α2-HS glycoprotein/fetuin, a transforming growth factor-β/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. Journal of Biological Chemistry 277: 19991-19997.
21. Rochette CN, Rosenfeldt S, Heiss A, et al. (2009): A Shielding Topology Stabilizes the Early Stage Protein–Mineral Complexes of Fetuin‐A and Calcium Phosphate: A Time‐Resolved Small‐Angle X‐ray Study. Chembiochem 10: 735-740
22. Wang H and Tracey K. (2002): Fetuin opsonizes macrophage-deactivating cations. Immune Response in the Critically Ill. Springer, 155-163
23. Veas F. (2011): Acute phase proteins: regulation and functions of acute phase proteins: BoD–Books on Demand.
24. Dziegielewska K, Andersen N and Saunders N. (1998): Modification of macrophage response to lipopolysaccharide by fetuin. Immunology letters 60: 31-35.
25. Uysal S, Yılmaz FM, Karatoprak K, et al., (2014): The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis. Eur Rev Med Pharmacol Sci ;18(22):3453–8.
26. Gerdes S, Osadtschy S, Buhles N, et al,. (2014):  Cardiovascular biomarkers in patients with psoriasis. Experimental dermatology ;23: 322-325.
27. Genc M, Can M, Guven B, et al., (2017):  Evaluation of Serum Fetuin-A and Osteoprotegerin Levels in Patients with Psoriasis. Indian J Clin Biochem; 32: 90-94.
28. Przepiera-Będzak H, Fischer K and Brzosko M. (2016): Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. International journal of molecular sciences ;17: 1255.
29. Abali R, Celik C, Tasdemir N, et al., (2013): The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A concentration and carotid intima-media thickness in women with polycystic ovary syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology; 169: 45-49.
30. Díaz M, Gallego-Escuredo JM, López-Bermejo A, et al., (2018): Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome. International journal of endocrinology ;
31. Gulhan I, Bozkaya G, Oztekin D, et al., (2012): Serum Fetuin-A levels in women with polycystic ovary syndrome. Archives of gynecology and obstetrics; 286: 1473-1476
32. Heiss A, DuChesne A, Denecke B, et al. (2003): Structural basis of calcification inhibition by α2-HS glycoprotein/fetuin-A formation of colloidal calciprotein particles. Journal of Biological Chemistry 278: 13333-13341.
33. Mosa O, Mohamad I and Salama M. (2012): Relationship between fetuin-A and systemic lupus erythematosus as a predictor marker for atherosclerosis. Am Med J 3: 249-254.
34. Price PA and Lim JE. (2003): The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. Journal of Biological Chemistry 278: 22144-22152.
35. Dahdal S, Devetzis V, Chalikias G, et al. (2018): Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus. PloS one 13: e0188695.
36. Reinauer C, Reinehr T, Baechle C, et al., (2018): Relationship of Serum Fetuin A with Metabolic and Clinical Parameters in German Children and Adolescents with Type 1 Diabetes. Hormone research in paediatrics; 89: 73-81.
37. Hendig D, Schulz V, Arndt M, et al., (2006):  Role of serum fetuin-A, a major inhibitor of systemic calcification, in pseudoxanthoma elasticum. Clinical chemistry; 52: 227-234.
38. Kozakowski J, Jeske W and Zgliczyński W. (2014): Fetuin-A levels in lean and obese women with polycystic ovary syndrome. Endokrynologia Polska 65: 371-376.
39. Chung HS, Lee HJ, Hwang SY, et al., (2018): Relationship of Circulating Fetuin-A Levels with Body Size and Metabolic Phenotypes. International journal of endocrinology; 8
40. Uyar B, Akyıldız M, Solak A, et al., (2015): Relationship between serum fetuin-A levels and carotid intima-media thickness in turkish patients with mild to moderate psoriasis. A case-control study. Acta dermatovenerologica Croatica; 23: 171-171.
41. Okan, G., Baki, A. M., Yorulmaz, E.et al.,  (2016): Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity. Journal of clinical laboratory analysis;30(4), 284-289.
42. Sak S, Uyanikoglu H, Incebiyik A, et al. (2018): Associations of serum fetuin-A and oxidative stress parameters with polycystic ovary syndrome.Clin Exp Reprod Med 45: 116-121.
43. Oikawa O, Higuchi T, Yamazaki T, et al. (2007): Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis. Clinical and experimental nephrology 11: 304-308.

Ahmad Shakib A.Wahab